170 related articles for article (PubMed ID: 25151734)
1. [Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
Wang K; Li Y; Zhang LJ; Yang HZ; Chen XG; Feng ZQ
Yao Xue Xue Bao; 2014 May; 49(5):639-43. PubMed ID: 25151734
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
Yao J; He Z; Chen J; Sun W; Fang H; Xu W
Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
[TBL] [Abstract][Full Text] [Related]
3. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
Qin AF; Li Y; Song HR; Chen XG; Jin XF; Wang K; Zhang LJ; Huo LC; Feng ZQ
Yao Xue Xue Bao; 2012 Dec; 47(12):1623-9. PubMed ID: 23460968
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
Lu CS; Tang K; Li Y; Jin B; Yin DL; Ma C; Chen XG; Huang HH
Yao Xue Xue Bao; 2013 May; 48(5):709-17. PubMed ID: 23888694
[TBL] [Abstract][Full Text] [Related]
5. [Synthesis and biological evaluation of sorafenib thiourea derivatives].
Yang Z; Fang Z; Wang ZX; Wei P
Yao Xue Xue Bao; 2011 Sep; 46(9):1093-7. PubMed ID: 22121780
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
Bioorg Med Chem Lett; 2015 Apr; 25(8):1692-1699. PubMed ID: 25801936
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
Wang M; Xu S; Lei H; Wang C; Xiao Z; Jia S; Zhi J; Zheng P; Zhu W
Bioorg Med Chem; 2017 Oct; 25(20):5754-5763. PubMed ID: 28927801
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W
Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, activity and docking studies of phenylpyrimidine-carboxamide Sorafenib derivatives.
Wang W; Wu C; Wang J; Luo R; Wang C; Liu X; Li J; Zhu W; Zheng P
Bioorg Med Chem; 2016 Dec; 24(23):6166-6173. PubMed ID: 28340913
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.
Wu C; Wang M; Tang Q; Luo R; Chen L; Zheng P; Zhu W
Molecules; 2015 Oct; 20(10):19361-71. PubMed ID: 26512636
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold.
Bao G; Du B; Ma Y; Zhao M; Gong P; Zhai X
Med Chem; 2016; 12(5):489-98. PubMed ID: 26740207
[TBL] [Abstract][Full Text] [Related]
13. Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities.
Fahmy HH; Khalifa NM; Ismail MM; El-Sahrawy HM; Nossier ES
Molecules; 2016 Feb; 21(3):271. PubMed ID: 26927048
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
Yao JW; Sun W; Chen J; Xu WF
Yao Xue Xue Bao; 2012 Sep; 47(9):1111-9. PubMed ID: 23227538
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides.
Wang M; Wu C; Xu S; Zhu Y; Li W; Zheng P; Zhu W
Med Chem; 2017; 13(2):176-185. PubMed ID: 27855595
[TBL] [Abstract][Full Text] [Related]
16. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
Chu JH; Zhao CR; Song ZY; Wang RQ; Qin YZ; Li WB; Qu XJ
Biomed Pharmacother; 2014 Apr; 68(3):335-41. PubMed ID: 24581722
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and In Vitro Antiproliferative Activity of New 1-Phenyl-3-(4-(pyridin-3-yl)phenyl)urea Scaffold-Based Compounds.
Al-Sanea MM; Ali Khan MS; Abdelazem AZ; Lee SH; Mok PL; Gamal M; Shaker ME; Afzal M; Youssif BGM; Omar NN
Molecules; 2018 Jan; 23(2):. PubMed ID: 29385071
[TBL] [Abstract][Full Text] [Related]
19. Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: design, synthesis, and antiproliferative activity against melanoma cell line.
Cho HJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Choi JH; Yoo KH
Chem Pharm Bull (Tokyo); 2013; 61(7):747-56. PubMed ID: 23812399
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
